Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 6/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8777019 | 0.87 | MBNL1 (0.45) | MBNL1ARCYP1A2NPC1L3MBTL1 | |
| SCHEMBL8776465 | 0.87 | MBNL1 (0.45) | MBNL1ARCYP1A2NPC1L3MBTL1 | |
| SCHEMBL8776610 | 0.87 | MBNL1 (0.41) | MBNL1ARCYP1A2L3MBTL1CASP3 | |
| SCHEMBL8776661 | 0.86 | MBNL1 (0.46) | MBNL1ARCYP1A2NPC1L3MBTL1 | |
| SCHEMBL8776676 | 0.84 | MBNL1 (0.44) | MBNL1ARCYP1A2NPC1 | |
| SCHEMBL8776859 | 0.84 | CYP1A2 (0.43) | MBNL1ARCYP1A2NPC1 | |
| SCHEMBL8776992 | 0.84 | MBNL1 (0.56) | MBNL1ARCYP1A2NPC1L3MBTL1 | |
| SCHEMBL8776542 | 0.83 | MBNL1 (0.40) | MBNL1ARCYP1A2NPC1L3MBTL1 | |
| SCHEMBL8776665 | 0.83 | MBNL1 (0.40) | MBNL1ARCYP1A2NPC1 | |
| SCHEMBL3793053 | 0.83 | CYP1A2 (0.44) | MBNL1ARCYP1A2NPC1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | MBNL1 4381/4885AR 3869/4885FFAR1 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.